Predictive and prognostic factors in RCC

**Location:** Room 7, Capital suite (level 3)

**Chairs:** A. Mattei, Luzern (CH)
M. Oya, Tokyo (JP)
B. Peyronnet, Rennes (FR)

**Aims and objectives of this session**
To discuss various predictive and prognostic factors in RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

640

**Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study**

*By:* Kim K.S.¹, Kim H.W.², Kim J.C.³, Kwak C.⁴, Kim Y.-J.⁵, Kang S.H.⁶, Byun S-S.⁷, Kim S.H.¹, Hong S-H.⁸

*Institutes:* Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Incheon, South Korea, ²St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Seoul, South Korea, ³Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea, ⁴Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Cheongju, Korea., Dept. of Urology, Cheongju, South Korea, ⁶Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁷Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, ⁸College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

641

**Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis**

*By:* Larcher A.¹, Muttin F.¹, Nini A.¹, Trevisani F.¹, Ripa F.¹, Cianflone F.¹, Carenzi C.¹, Dell'Oglio P.¹, Rigatti P.², Dehó F.³, Montorsi F.¹, Capitanio U.¹, Bertini R.¹

*Institutes:* IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Milan, Italy, ²Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

642

**External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus**


*Institutes:* Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ²University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, ³University Vita-Salute, Dept. of Urology, Milan, Italy, ⁴Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, ⁵University of Miami, Dept. of Urology, Miami, United States of America, ⁶University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁷University of California-Davis, Dept. of Urology, Sacramento, United States of America, ⁸University of Turin, Dept. of Urology, Turin, Italy, ⁹University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹⁰University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹¹New York University School of Medicine, Dept. of Urology, New York, United States of America, ¹²
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S., Hsu R., Blick C., Goh V., Hanbury D., Nathan P., Nicol D., Watson C., Wilson E., Stewart G.

Institutes: Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, Guy's & St Thomas' Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma


Institutes: IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients


Institutes: University Hospital Mainz, Dept. of Urology, Mainz, Germany, University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, Medical University of Vienna, Dept. of Urology, Vienna, Austria, Instituto Nacional De Cancerología, Dept. of Urology, Mexico, Mexico, Carl-Thiem-Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, Julius–Maximilians–University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, Charles University In Pilsen, Dept. of Urology, Pilsen, Czech Republic, Medical University Graz, Dept. of Urology, Graz, Austria, Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, Ludwig–Maximilians–University, Dept. of Urology, Munich, Germany

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease


Institutes: University Hospital Infanta Sofia, Dept. of Urology, Madrid, Spain, Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, Fundació Puigvert, Dept. of Urology, Barcelona, Spain, University of North Carolina, Dept. of Urology, Chapel Hill, United States of America, Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, University of Würzburg, Dept. of Urology, Würzburg, Germany, University of Eastern Piedmont, Dept. of Urology, Novara, Italy, Hospital Universitario Y Politècnico La Fe, Dept. of Urology, Valencia, Spain, Medical University of Graz, Dept. of Urology, Graz, Austria, Lahey Clinic, Dept. of Urology, Burlington, United States of America
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S., Beisland C., Gudmundsson E., Stewart G., Lam T., Gietzmann W., Zakikhani P., Marconi L., Williams S., Powles T., Van Werkhoven E., Meijer R.P., Ljungberg B., Bex A.

Institutes: Lund University, Dept. of Clinical Sciences, Malmö, Sweden; Haukeland University Hospital, Dept. of Urology, Bergen, Norway; Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland; University of Cambridge, Academic Urology Group, Cambridge, United Kingdom; University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom; Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom; Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal; Queen Mary University of London, Barts Cancer Institute, London, United Kingdom; University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; San Pio Da Pietrelcina Hospital, Vasto, Italy; University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; San Pio Da Pietrelcina Hospital, Vasto, Italy; St. Elisabeth-Hospital Straubing, Germany; University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; Ludwig-Maximilians-University, Munich, Germany; University of Munich, Munich, Germany.

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis


Institutes: Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America; Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America; Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America; Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America; University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany; Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America.

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America.

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell
651

Utility of chest x-ray in follow-up of pT1 renal cell carcinoma

By: Rizzo M.1, Umari P.1, Pavan N.1, Liguori G.1, Verzotti E.1, Cancellieri L.1, Mottrie A.2, Minervini A.3, Trombetta C.3

Institutes: 1Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, 2Onze-Lieve-Vrouwziekenhuis, Dept. of Urology, Aalst, Belgium, 3University Hospital Careggi, Dept. of Urology, Florence, Italy

652

Organ confined renal cell carcinoma - are the current guidelines sufficient?

By: Frees S.1, Kamal M.1, Nestler S.2, Bidnur S.3, Neisius A.1, Jaeger W.1, Thomas C.1, Thüroff J.4, Roos F.1

Institutes: 1University Medical Center, Dept. of Urology, Mainz, Germany, 2Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, 3Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, 4University Medical Center, Dept. of Urology, Mannheim, Germany

653

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study

By: Tondut L.1, Peyronnet B.1, Bernhard J.-C.2, Vaessen C.2, Doumerc N.3, Sebe P.5, Pradere B.6, Guillonneau B.5, Nouhaud F.X.7, Brichart N.8, Alimi Q.1, Beauval J.-B.4, Rammal A.9, De La Taille A.10, Baumert H.11, Droupy S.12, Bruyere F.5, Roupret M.3, Mejean A.13, Bensalah K.1


654

Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data

By: Camp C.1, O’Hara J.1, Hughes D.1, Adshead J.2

Institutes: 1Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, 2Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom